Floating Genes develops liquid biopsy-based in vitro diagnostic tests utilizing their proprietary Enhance-seq technology, which employs NGS-based targeted sequencing to detect rare circulating tumor DNA (ctDNA) amidst a background of non-mutated DNA. This technology enables early cancer diagnosis by identifying low-frequency mutations with minimal sequencing depth, addressing the challenge of detecting cancer at its earliest stages.
Funding
Funding not disclosed
Founders
Product
Problem
Early cancer detection is hindered by the difficulty of identifying rare circulating tumor DNA (ctDNA) fragments within a large background of non-mutated DNA, often requiring deep sequencing and complex analysis. Traditional methods struggle to detect these low-frequency mutations with sufficient sensitivity for early diagnosis.
Solution
Floating Genes is developing in vitro diagnostic tests based on liquid biopsy, utilizing their proprietary Enhance-seq technology to address the challenge of early cancer detection. Enhance-seq employs NGS-based targeted sequencing to detect rare ctDNA molecules, even when present in low concentrations. This technology enables highly sensitive detection of low-frequency mutations with minimal sequencing depth, facilitating earlier cancer diagnosis.
Target Audience
The primary target audience includes clinical laboratories, oncologists, and diagnostic companies focused on early cancer detection and personalized medicine.
Features
- Enhance-seq technology for NGS-based targeted sequencing of ctDNA
- High sensitivity for detecting rare mutations in a background of non-mutated DNA
- Low sequencing depth requirements for cost-effective analysis
- Liquid biopsy-based in vitro diagnostic tests